Dublin, March 08, 2022 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Deals Analysis" report has been added to ResearchAndMarkets.com's offering.
A lot of attention is being given to the areas related to cell and gene therapy (CGT) recently. There are now many approved therapies with proven track records.
As the tools have lowered the barriers to entry for the industry, over a thousand companies have been created or become involved.
In concert with the technologies progressing and the proven benefits, CGT-related companies have received growing amounts of funding - and it appears likely that the trend will continue. How do you keep up with this high-interest field?
This report, Cell and Gene Therapy Deals Analysis, analyzes the deals, including:
- IPO and FPO Deals
- SPAC Deals
- Venture Capital and Private Funding
- Strategic Investments
- Mergers & Acquisitions (M&A)
- Technology and Research Collaborations
- Licensing Deals
- Manufacturing and Supply Chain Deals
- Public Outreach, Consumer Education, & Philanthropy
- Distribution & Co-marketing Deals
- Restructurings, Joint Ventures, Terminations and Spinoffs
- Other Types of Deals Impacting Cell and Gene Therapy
In any novel technology field, the initial significant marketplace will be in financing and company starts. They are notoriously hard to track. The analysts have already done the work for readers in this volume.
This report categorizes hundreds of cell and gene therapy deals into a usable format. Charts help to illustrate the different types of deals and frequency of different types of deals and how the deals activity in 2021 changed per quarter.
This is an essential resource that every market watcher in Cell and Gene Therapy will need. For updated information on cell and gene therapy deals on a regular basis.
Key Topics Covered:
Chapter 1: Executive Summary
- Introduction
- $70.8 Billion in Funding During 2021
- Quarterly Funding in 2021
- 916 Total Cgt Announcements from January 2021 Through January 2022
- Uptick in Collaborations, Acquisitions, and Manufacturing/Supply Chain Deals Highlight Activity in Cell and Gene Therapy
- A Look at Less Frequent CGT Deal Types
Chapter 2: Venture Capital & Private Funding
- Vc/Private Funding in Flux
Chapter 3: Strategic Investments
- Strategic Investments in Cell and Gene Therapy
Chapter 4: IPOs, FPOss, & SPACs
- North America Sees the Majority of Proceeds from IPOs, FPOs, and SPACs
Chapter 5: Mergers & Acquisitions (M&A)
- Spike in M&A Activity During Q3 2021
Chapter 6: Technology/Research/Strategic Collaborations
- Cgt Market Sees a Broad Variety of Collaborations
Chapter 7: Licensing
- A Look at Licensing in the Cell and Gene Therapy Market
Chapter 8: Manufacturing and Supply Chain
- Examining Manufacturing and Supply Chain Management Activity in Cgt
Chapter 9: Public Outreach, Consumer Education, & Philanthropy
- Cgt Market Has Dozens of Announcements Related to Public Outreach, Patient/Consumer Education, and Philanthropy
Chapter 10: Distribution & Co-Marketing
- A Look at Cgt Distribution and Co-Marketing Deals
Chapter 11: Other - Conclusion, Restructuring, Jv, Termination, Spinoffs
- A Look at Other Types of Deals Impacting Cell and Gene Therapy Mirrors and High Costs
For more information about this report visit https://www.researchandmarkets.com/r/uvjrkn
